HBV-IN-25 NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: HBV-IN-25 | CAS No.: 2161364-69-6 |
| Supply Ability: 10g | Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | HBV-IN-25 |
| Description | HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA＞452 μg/mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1]. |
| In vitro | HBV-IN-25, at concentrations ranging from 8-50 μM over a period of 5 days, exhibits anti-HBeAg potency, demonstrated by an IC50 value of 0.58 μM. Additionally, its anti-HBV activity in primary human hepatocytes (PHH) remains consistent or shows a slight decrease, with an IC50 value of 1.15 μM [1]. |
| In vivo | HBV-IN-25, administered orally at doses of 5, 20, 100, and 300 mg/kg, exhibits favorable pharmacokinetic (PK) attributes and demonstrates remarkable effectiveness in markedly lowering levels of HBV antigens, DNA, and intrahepatic cccDNA as evidenced in the HBVcircle mouse model. The pharmacokinetic parameters for each dosage showed a proportional increase in both maximum concentration (C max) and area under the curve (AUC), indicating significant drug absorption and sustained presence in the system. Furthermore, dose-dependent effects were observed in terminal body weight changes, spinal cord inflammation, demyelination, and the count of apoptotic cells in spinal cord sections, thereby underscoring the compound’s efficacy and potential therapeutic implications. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Inhibitors Related | Doxorubicin hydrochloride | Osthole | Lamivudine | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Estradiol benzoate | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Nicotinamide | Osalmid | Bifendate |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $44.00/10mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-25 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-05-21 | |
| $1.00/1kg |
VIP3Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2024-01-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY